Co-Diagnostics (NASDAQ:CODX) & CVRx (NASDAQ:CVRX) Head-To-Head Review

CVRx (NASDAQ:CVRX) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Institutional & Insider Ownership

75.3% of CVRx shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 18.9% of CVRx shares are owned by insiders. Comparatively, 6.1% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

CVRx has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -0.63, indicating that its share price is 163% less volatile than the S&P 500.

Profitability

This table compares CVRx and Co-Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CVRx	-116.91%	-93.06%	-51.78%
Co-Diagnostics	-563.93%	-54.94%	-49.28%

Analyst Ratings

This is a summary of recent recommendations for CVRx and Co-Diagnostics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	0	1	6	0	2.86
Co-Diagnostics	0	1	0	0	2.00

CVRx presently has a consensus target price of $17.83, suggesting a potential upside of 30.73%. Co-Diagnostics has a consensus target price of $1.50, suggesting a potential upside of 111.27%. Given Co-Diagnostics’ higher probable upside, analysts plainly believe Co-Diagnostics is more favorable than CVRx.

Valuation and Earnings

This table compares CVRx and Co-Diagnostics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$51.29 million	6.93	-$59.97 million	($2.69)	-5.07
Co-Diagnostics	$6.81 million	3.33	-$35.33 million	($1.38)	-0.51

Co-Diagnostics has lower revenue, but higher earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Summary

CVRx beats Co-Diagnostics on 8 of the 14 factors compared between the two stocks.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

About Co-Diagnostics

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.